Harriet Eldredge-Hindy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harriet Eldredge-Hindy has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Nicole L. Simone
Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
3 shared publications Pramila R. Anne
Department of Radiation Oncology
3 shared publications- Adam P. Dicker
Thomas Jefferson University, Philadelphia, PA 19107, USA
2 shared publications - Joshua David Palmer
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2 shared publications - Kosj Yamoah
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
2 shared publications - Robert B. Den
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
2 shared publications
Latest Publications
- 9 November 2024
- Published by Elsevier in Brachytherapy
- Vol. 24 (1) , 154-161
Anticoagulation management in gynecologic brachytherapy patients with perioperative or chronic thromboembolic disease: A retrospective analysis
- 9 November 2024
- Published by Elsevier in Brachytherapy
- Vol. 24 (1) , 154-161
Anticoagulation management in gynecologic brachytherapy patients with perioperative or chronic thromboembolic disease: A retrospective analysis
- 1 October 2021
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 114 (10) , 630-635
Trends in Incidence and Mortality Rates of Uterine Cancer in Kentucky
Objectives: The objective of this analysis was to gauge how the incidence and mortality of uterine cancer in Kentucky have changed from 1995 through 2017. An assessment of the trends in incidence and mortality across different geographic areas and between different races was also performed. Methods: Age-adjusted annual incidence and mortality rates for uterine cancer were obtained from the...
- 1 October 2021
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 114 (10) , 630-635
Trends in Incidence and Mortality Rates of Uterine Cancer in Kentucky
Objectives: The objective of this analysis was to gauge how the incidence and mortality of uterine cancer in Kentucky have changed from 1995 through 2017. An assessment of the trends in incidence and mortality across different geographic areas and between different races was also performed. Methods: Age-adjusted annual incidence and mortality rates for uterine cancer were obtained from the...
- Open Access
- 11 September 2021
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 6 (6) , 100782
Development of a Financial Toxicity Screening Tool for Radiation Oncology: A Secondary Analysis of a Pilot Prospective Patient-Reported Outcomes Study
- 11 September 2021
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 6 (6) , 100782
Open AccessDevelopment of a Financial Toxicity Screening Tool for Radiation Oncology: A Secondary Analysis of a Pilot Prospective Patient-Reported Outcomes Study
- 11 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 5893-5894
ASO Author Reflections: Five-Fraction Whole-Breast Radiation: Let’s Make Adjuvant Therapy Accessible
- 11 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 5893-5894
ASO Author Reflections: Five-Fraction Whole-Breast Radiation: Let’s Make Adjuvant Therapy Accessible
- 1 April 2016
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 39 (2) , 189-195
Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma
Objectives: To report outcomes after yttrium-90 microsphere brachytherapy for unresectable liver metastases from uveal melanoma and to evaluate factors predictive for overall survival (OS) and hepatic progression-free survival (PFS). Methods: A total of 71 patients were consecutively treated with microsphere brachytherapy for unresectable liver metastases from uveal melanoma between 2007 and 2012. Clinical, radiographic, and positron emission tomography–derived, functional tumor parameters were evaluated by log-rank test in univariate analysis and backwards stepwise multivariate Cox proportional hazards regression. OS and hepatic PFS were estimated by Kaplan-Meier analysis. Results: A total of 134 procedures were performed in 71 patients with a median age of 63 years (range, 23 to 91 y). Fifty-eight patients (82%) received microsphere brachytherapy as a salvage therapy. Median hepatic PFS and OS after microsphere brachytherapy were 5.9 months (range, 1.3 to 19.1 mo) and 12.3 months (range, 1.9 to 49.3 mo), respectively. Median OS times after diagnosis of liver metastases was 23.9 months (range, 6.2 to 69.0 mo). In univariate analysis, female sex, pretreatment metabolic tumor volume, and total glycolic activity (TGA) were significantly correlated with hepatic PFS and OS. In multivariate analysis, female sex and TGA retained significance as independent predictors of hepatic PFS and OS. A low pretreatment TGA (P=0.01). Conclusions: Yttrium-90 microsphere brachytherapy provided favorable survival times in patients with unresectable liver metastases from uveal melanoma. Metabolic tumor volume and TGA are predictive functional tumor parameters, which may aid patient selection and risk stratification.
- 1 April 2016
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 39 (2) , 189-195
Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma
Objectives: To report outcomes after yttrium-90 microsphere brachytherapy for unresectable liver metastases from uveal melanoma and to evaluate factors predictive for overall survival (OS) and hepatic progression-free survival (PFS). Methods: A total of 71 patients were consecutively treated with microsphere brachytherapy for unresectable liver metastases from uveal melanoma between 2007 and 2012. Clinical, radiographic, and positron emission tomography–derived, functional tumor parameters were evaluated by log-rank test in univariate analysis and backwards stepwise multivariate Cox proportional hazards regression. OS and hepatic PFS were estimated by Kaplan-Meier analysis. Results: A total of 134 procedures were performed in 71 patients with a median age of 63 years (range, 23 to 91 y). Fifty-eight patients (82%) received microsphere brachytherapy as a salvage therapy. Median hepatic PFS and OS after microsphere brachytherapy were 5.9 months (range, 1.3 to 19.1 mo) and 12.3 months (range, 1.9 to 49.3 mo), respectively. Median OS times after diagnosis of liver metastases was 23.9 months (range, 6.2 to 69.0 mo). In univariate analysis, female sex, pretreatment metabolic tumor volume, and total glycolic activity (TGA) were significantly correlated with hepatic PFS and OS. In multivariate analysis, female sex and TGA retained significance as independent predictors of hepatic PFS and OS. A low pretreatment TGA (P=0.01). Conclusions: Yttrium-90 microsphere brachytherapy provided favorable survival times in patients with unresectable liver metastases from uveal melanoma. Metabolic tumor volume and TGA are predictive functional tumor parameters, which may aid patient selection and risk stratification.
- 1 May 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (3) , 162-168
Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold
- 1 May 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (3) , 162-168
Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold
- 1 January 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (1) , 4-10
Active Breathing Coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: Report of a prospective trial
- 1 January 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (1) , 4-10
Active Breathing Coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: Report of a prospective trial
- 1 September 2014
- Published by Elsevier in Brachytherapy
- Vol. 13 (5) , 456-464
Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
- 1 September 2014
- Published by Elsevier in Brachytherapy
- Vol. 13 (5) , 456-464
Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
- Open Access
- 10 August 2014
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2014, 1-12
Intraoperative Radiotherapy for Breast Cancer: The Lasting Effects of a Fleeting Treatment
In well-selected patients who choose to pursue breast conservation therapy (BCT) for early-stage breast cancer, partial breast irradiation (PBI) delivered externally or intraoperatively, may be a viable alternative to conventional whole breast irradiation. Two large, contemporary randomized trials have demonstrated breast intraoperative radiotherapy (IORT) to be noninferior to whole breast external beam radiotherapy (EBRT) when assessing for ipsilateral breast tumor recurrence in select patients. Additionally, IORT and other PBI techniques are likely to be more widely adopted in the future because they improve patient convenience by offering an accelerated course of treatment. Coupled with these novel techniques for breast radiotherapy (RT) are distinct toxicity profiles and unique cosmetic alterations that differ from conventional breast EBRT and have the potential to impact disease surveillance and patient satisfaction. This paper will review the level-one evidence for treatment efficacy as well as important secondary endpoints like RT toxicity, breast cosmesis, quality of life, patient satisfaction, and surveillance mammography following BCT with IORT. In well-selected patients who choose to pursue breast conservation therapy (BCT) for early-stage breast cancer, partial breast irradiation (PBI) delivered externally or intraoperatively, may be a viable alternative to conventional whole breast irradiation. Two large, contemporary randomized trials have demonstrated breast intraoperative radiotherapy (IORT) to be noninferior to whole breast external beam radiotherapy (EBRT) when assessing for ipsilateral breast tumor recurrence in select patients. Additionally, IORT and other PBI techniques are likely to be more widely adopted in the future because they improve patient convenience by offering an accelerated course of treatment. Coupled with these novel techniques for breast radiotherapy (RT) are distinct toxicity profiles and unique cosmetic alterations that differ from conventional breast EBRT and have the potential to impact disease surveillance and patient satisfaction. This paper will review the level-one evidence for treatment efficacy as well as important secondary endpoints like RT toxicity, breast cosmesis, quality of life, patient satisfaction, and surveillance mammography following BCT with IORT.
- 10 August 2014
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2014, 1-12
Open AccessIntraoperative Radiotherapy for Breast Cancer: The Lasting Effects of a Fleeting Treatment
In well-selected patients who choose to pursue breast conservation therapy (BCT) for early-stage breast cancer, partial breast irradiation (PBI) delivered externally or intraoperatively, may be a viable alternative to conventional whole breast irradiation. Two large, contemporary randomized trials have demonstrated breast intraoperative radiotherapy (IORT) to be noninferior to whole breast external beam radiotherapy (EBRT) when assessing for ipsilateral breast tumor recurrence in select patients. Additionally, IORT and other PBI techniques are likely to be more widely adopted in the future because they improve patient convenience by offering an accelerated course of treatment. Coupled with these novel techniques for breast radiotherapy (RT) are distinct toxicity profiles and unique cosmetic alterations that differ from conventional breast EBRT and have the potential to impact disease surveillance and patient satisfaction. This paper will review the level-one evidence for treatment efficacy as well as important secondary endpoints like RT toxicity, breast cosmesis, quality of life, patient satisfaction, and surveillance mammography following BCT with IORT. In well-selected patients who choose to pursue breast conservation therapy (BCT) for early-stage breast cancer, partial breast irradiation (PBI) delivered externally or intraoperatively, may be a viable alternative to conventional whole breast irradiation. Two large, contemporary randomized trials have demonstrated breast intraoperative radiotherapy (IORT) to be noninferior to whole breast external beam radiotherapy (EBRT) when assessing for ipsilateral breast tumor recurrence in select patients. Additionally, IORT and other PBI techniques are likely to be more widely adopted in the future because they improve patient convenience by offering an accelerated course of treatment. Coupled with these novel techniques for breast radiotherapy (RT) are distinct toxicity profiles and unique cosmetic alterations that differ from conventional breast EBRT and have the potential to impact disease surveillance and patient satisfaction. This paper will review the level-one evidence for treatment efficacy as well as important secondary endpoints like RT toxicity, breast cosmesis, quality of life, patient satisfaction, and surveillance mammography following BCT with IORT.
- Open Access
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 262-270
Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer
Purpose: To report outcomes following adjuvant high-dose-rate vaginal brachytherapy (VBT) with or without chemotherapy for high-intermediate risk (HIR) and high-risk, early stage endometrial cancer as defined in Gynecologic Oncology Group trial 0249. Material and methods: From May 2000 to...
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 262-270
Open AccessAdjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer
Purpose: To report outcomes following adjuvant high-dose-rate vaginal brachytherapy (VBT) with or without chemotherapy for high-intermediate risk (HIR) and high-risk, early stage endometrial cancer as defined in Gynecologic Oncology Group trial 0249. Material and methods: From May 2000 to...